Xenetic Biosciences Inc（XBIO）の株式分析XBIOXenetic Biosciences Inc

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Xenetic Biosciences Inc is a good buy right now due to its recent performance and positive financial indicators. The stock has shown a 20-day change of +57.00% and a year-to-date change of +85.12%, indicating strong momentum. Additionally, the company's gross margin remains at an impressive 100% for recent quarters, showcasing its ability to maintain profitability on revenue despite net losses. However, the main risk lies in the net income, which reported a loss of approximately $929,695 in Q2 2026, indicating ongoing financial challenges that investors should monitor closely.

1 analysts cover XBIO: 1 rate it Buy, 0 Hold and 0 Sell.